Allogeneic CART-NKG2D cells

Phase 2Cell therapy

IInstituto de Investigación Hospital Universitario La Paz

Allogeneic CART-NKG2D cells is one of 118 biologic programs targeting Abdominal Aortic Aneurysm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Abdominal Aortic AneurysmActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Ulcerative ColitisActive, not recruiting

Heart FailureActive, not recruiting

Abdominal Aortic AneurysmPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Ulcerative ColitisPhase 1/Phase 2

Active, not recruiting

Heart FailurePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Allogeneic CART-NKG2D cells

IInstituto de Investigación Hospital Universitario La Paz

Phase 2

1 2

Amidate

Pfizer

Preclinical

1 3

Monoferric

PPharmacosmos A/S

Preclinical

5 4

Savaysa

Daiichi Sankyo

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Xifaxan

SSalix

Preclinical

2 7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Heart Failure

NCT06840275

Q4 2030

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT06709469

Clinical

Trials by Indication[1]

Not yet recruiting·CCell to Cure ApS·Phase 2·NCT06840275·90 enrolled

Abdominal Aortic Aneurysm1 trial

Abdominal Aortic Aneurysm Stabilization With Truncal Cells: Controlled Clinical Trial With Historical Cohorts

Recruiting·IInstituto de Investigación Hospital Universitario La Paz·Phase 2·NCT06488898·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Allogeneic CART-NKG2D cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allogeneic CART-NKG2D cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allogeneic CART-NKG2D cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto de Investigación Hospital Universitario La Paz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: IInstituto de Investigación Hospital Universitario La Paz

Allogeneic CART-NKG2D cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2030

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Ulcerative Colitis1 trial

Heart Failure1 trial

Abdominal Aortic Aneurysm1 trial

References

Drug Info

Quick Facts

Related News